Meridian Women's Health powered by

Menopause Transition Tracking Report

Sarah Mitchell Age 49 Visit 6 · Nov 24, 2026 LMP Oct 2, 2025 as reported 45 weeks of tracking · 43 weekly check-ins

V1 · Jan 12

V2 · Feb 23

RX STARTED

V3 · Apr 20

V4 · Jun 22

RX ADDED

V5 · Sep 1

RX DOSE INCREASED

V6 · Nov 24

THIS VISIT

No red-flag symptoms in self-report · absence of a report does not rule out a symptom For use by the treating clinician only

The clinical read

Changed Brain fog lower since week 35, following the reported estradiol increase (0.75 to 1.5 mg/day) at V5. Hot flashes and sleep remain low.

Unchanged Hair thinning · reduced libido · urinary urgency.

Since last visit Estradiol transdermal cream increased from 0.75 to 1.5 mg/day (1 to 2 pumps) at V5, as reported. No new side effects reported. Spotting not reported since V5. Added magnesium glycinate 300 mg at bedtime, week 24, as reported.

She wants To keep everything exactly as it is. Wants to discuss: staying the courseHair thinning

Forty-five weeks, as she reported them

Self-report · weekly check-ins · 0–10

Hot flashes Sleep disruption Brain fog

The three lines are the symptoms the patient raised as her visit priorities. The full picture across all 100 surveyed symptoms is below. The therapy timeline is shown on a separate track. Lower = fewer symptoms, 0–10, as reported. Clinical interpretation rests with the treating clinician.

Total reported burden · all 100 symptoms, summed weekly as reported

Sum of all her 0–10 ratings across the full 100-symptom survey, each week. Shows whether the whole picture is changing, beyond the symptoms she chose to focus on. Bronze lines mark the reported therapy events.

Daily-function domains, vs her own baseline only

Same scores the patient sees

Sleep

8.3 / 10

▲ was 3.9 at V1 · holding since V5

Energy

7.4 / 10

▲ was 6.8 at V5

Cognition

6.8 / 10

▲ was 5.0 through V5

Mood

7.2 / 10

▲ was 4.8 at V1

Symptom map

100

symptoms surveyed
at every check-in

14 active this visit19 at V5 · 44 at baseline

Hair, scalp & nails7● unchanged

Intimate & bladder5● unchanged

Strength & movement4● unchanged

Concentration & memory3▲ lower, was 6 at V5

Mood & emotions2▲ lower, was 6

Sleep & fatigue2▲ lower, was 7

Heat & cold2▲ lower, was 8

Rated consistently, never raised by the patient

Joint aches445 weeks present

Urinary urgency445 weeks present

Brittle nails438 weeks present

Surfaced automatically: rated above 3 in most check-ins but never selected by the patient as a visit priority. Shown so nothing she stopped mentioning goes unseen. Interpretation rests with the clinician.

All 14 rated symptoms, with change since baseline

Symptom	Cluster	Score	Vs baseline
Hair thinning	Hair, scalp & nails	7/10	● unchanged (was 7)
Reduced libido	Intimate & bladder	5/10	● unchanged (was 5)
Urinary urgency	Intimate & bladder	4/10	● unchanged (was 4)
Joint aches	Strength & movement	4/10	● unchanged (was 5)
Brittle nails	Hair, scalp & nails	4/10	● unchanged (was 4)
Word-finding lapses	Concentration & memory	3/10	▲ lower (was 6 at V5)
Difficulty concentrating	Concentration & memory	3/10	▲ lower (was 6 at V5)
Mood swings	Mood & emotions	2/10	▲ lower (was 6)
Early awakening	Sleep & fatigue	2/10	▲ lower (was 7)
Night sweats	Heat & cold	2/10	▲ lower (was 7)
Hot flashes	Heat & cold	2/10	▲ lower (was 8)
+ 3 additional symptoms rated 1–2, all unchanged; full list in the data export.

Objective digital signal · 14 samples since V5

Game-style sampling on her phone · not a neuropsychological assessment · within-patient change only

Processing speed

▲ Improving vs V5

Word retrieval

▲ Improving vs V5

Working memory

● Unchanged

Delayed recall

● Unchanged

Her reported fog is lower since week 35; cognitive sampling over the same period shows change in a positive direction. The two sources are consistent. Interpretation rests with the clinician. Hearing and vision sampling: steady across visits. Facial-signal sampling: steady across visits.

In her words

About two weeks after we went up to two pumps, I started finding my words again. I did not believe the fog could lift. I want to keep everything exactly as it is.

She wants: to stay the course; to ask about the hair thinning.

Quantified: word-finding lapses now once or twice a week, down from most days, as reported.

Supplements & other medications, as reported

Levothyroxine 50 mcgLong-standing

Daily, on waking, on an empty stomach. Reported unchanged since baseline.

Magnesium glycinate 300 mgAdded week 24

At bedtime, as reported; started on her own initiative before the V5 visit.

Vitamin D3 2000 IULong-standing

Daily, with breakfast. Reported unchanged.

Omega-3 1 gLong-standing

Daily. Reported unchanged.

As reported by the patient in her check-ins; shown so the full picture is in one place. Verification against the dispensing record rests with the clinic.

Between visits

1 update since V5

Light spottingNot reported since V5

Discussed at the V5 visit. No spotting reported in the 12 weeks since. Red-flag screen across all check-ins: clear.

Side effects after the V5 adjustmentNone reported

No new side effects reported in 12 weekly check-ins since the reported dose adjustment.

Reports containing red-flag terms are auto-highlighted and moved to the top of the clinic feed.

Clinical summary

[Source: MARKABLE wellness tracking, patient self-reported data. Not a medical device. | Visit 6 | 11/24/2026] Patient priorities Staying the course; hair thinning. Therapy as reported Estradiol transdermal cream 0.75 mg/day (1 pump) since Feb 23 (V2); increased to 1.5 mg/day (2 pumps) Sep 1 (V5). Micronized progesterone 100 mg at bedtime since Jun 22 (V4). LMP 10/02/2025 as reported. Supplements and other medications as reported Levothyroxine 50 mcg daily on waking, long-standing. Vitamin D3 2000 IU daily. Omega-3 1 g daily. Magnesium glycinate 300 mg at bedtime, self-started week 24. Reported change across visits Brain fog 6 through V5, lower from week 35, now 3; word-finding lapses now once or twice a week, down from most days. Cognitive sampling over the same period shows change in a positive direction, consistent with her report. Hot flashes and night sweats remain 2. Sleep disruption remains 2. Mood 7.2. Hair thinning, libido, urinary urgency unchanged. Side effects and events as reported No new side effects reported since the V5 adjustment. Light spotting discussed at V5; not reported since. No red-flag symptoms reported. Interpret in full clinical context; clinical judgment rests with the treating clinician.

History & safety screen

Medical, surgical, family and screening history, medications and allergies live in your EMR intake record. This report adds what the intake does not collect: her symptom picture, objective digital samples, and how both change over time.

Report No. 0006 · Visit 6 of ongoing Prepared Nov 24, 2026 · Meridian Women's Health

▲ reported change in a positive direction vs her own baseline ● unchanged / within her previously reported range as reported any value originating from self-report rather than a verified measurement

Wellness report based on patient self-report and brief digital sampling (facial-signal analysis from a selfie, game-style cognitive sampling, brief hearing and vision sampling). It reflects subjective experience and observed patterns and is not a substitute for clinical evaluation, diagnosis, or treatment decisions. It is not intended to diagnose, treat, cure, or prevent any disease, does not establish treatment efficacy, and contains no comparison to clinical norms. Cognitive wellness scores are game-based samples and do not constitute a neuropsychological assessment. The report is based on weekly check-ins and samples collected between visits. Data is stored securely with access limited to the care team.